Hi Eagle ... good summary. All I would add is:
1. The 75mg dosing study has commenced and the Final patient will be dosed on Monday.
2. The MAD Study will commence this month.
Accordingly data will flow fairly quickly on safety and efficacy.
3. The new IP application relates to a new undisclosed modality.
4. Human trials of PC001 (ADOA) will commence in Q3.
5. They are hoping to achieve Proof of Concept for all 3 drugs by end of 2025. (At this stage PYC003 is in H1 2026).
Ann: Q2 2024 Investor Webinar Presentation, page-12
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 17.5¢ | $508.8K | 2.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 118941 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 183634 | 2 |
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable